DSM has entered into negotiations with Adare Pharma Solutions to acquire Adare Biome, a developer and manufacturer of postbiotics, for an enterprise value of €275 million.
Adare Biome’s origins date back to 1907 when French chemist Pierre Boucard launched Lactéol, a supplement for relieving gut troubles. Available over the counter in 35 countries, Lactéol is said to be “one of the most scientifically well-documented microorganism-based therapeutics in the world in terms of efficacy and safety”.
DSM hopes to expand the availability of the supplement through its business-to-consumer unit, i-Health. In addition, the ingredients giant plans to further develop Adare Biome’s postbiotic business-to-business ingredient, while leveraging its potential in dietary supplements, early life and medical nutrition, and nutritional improvement for the under-nourished.
Tom Sellig, CEO of Adare Pharma Solutions, commented: “DSM would be the ideal company to take Adare Biome to a new level and realise the growth potential of postbiotics. They have the infrastructure and strong commercialisation and science capabilities to scale the significant scientific research achieved over the years, and DSM’s mission to create healthier lives for all will resonate strongly with the team.”
Philip Eykerman, DSM’s executive vice president health, nutrition & care, said: “Adare Biome would be a perfect fit for DSM, with pioneering science that will complement each of our three businesses. The Adare Biome team will greatly help in accelerating our ‘health from the gut’ strategy as there is considerable untapped potential for next-generation biotics to support the health of people and animals.”
The transaction remains subject to consultation with the workers council and customary regulatory conditions.
By Gwen Jones
Source: foodbev.com
In 2017, Sanofi partnered with the Lebanon, New Hampshire-based ImmuNext to develop an antibody for autoimmune diseases like lupus and multiple sclerosis, which included giving Sanofi a worldwide license to develop frexalimab. The agreement involved milestone payments upto $500 million.
Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has acquired Synaffix, a biotech company focused on the commercialisation of its clinical stage technology platform for the development of antibody-drug conjugates (ADCs).
In its hunt for the new head of its pharmaceutical systems business—which makes syringes, self-injection systems and other drug delivery devices for 70% of the top 100 drugmakers in the world, according to the company—BD landed on a candidate with plenty of experience among that customer group.
